ClinicalTrials.gg
CompletedNCT05477121Updated Feb 18, 2025

Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) with Connected Devices

An observational study in Epilepsy, Generalized, sponsored by Centre Hospitalier Universitaire Vaudois. Completed at 1 site in Switzerland. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Centre Hospitalier Universitaire Vaudois · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
12 Years and older
Sex
All
01

Study summary

By bringing together the fields of seizure detection and that of Sudden Unexpected Death in Epilepsy (SUDEP), the current project aims at delineating which set of biosensors and related biomarkers would optimally characterize the severity of GTCS and the associated risk of SUDEP.

Read the detailed description

The main objective is to to evaluate which of the five biosignals considered, being, electrodermal activity (EDA), heart rate (HR), accelerometry (AC), arm-measurement of skin electromyography (EMG), and bed sensing of body movement (BM), or any of their combinations, offers the most accurate detection and quantification of our primary indicator of GTCS-severity, i.e. postictal EEG suppression (PGES).

02

Conditions studied

  • Epilepsy, Generalized

Browse trials for

03

In context

Epilepsy, Generalized

39 studies on the registry are indexed under Epilepsy, Generalized; 4 are open to participants now.

This study's enrollment of 400 is above the median of 80 across 13 observational studies indexed under Epilepsy, Generalized.

Browse Epilepsy, Generalized studies →

Lead sponsor

Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A cohort of 500 patients with active epilepsy, undergoing Video-EEG monitoring in one of the participating epilepsy centers will be enrolled in this study with the aim to record epileptic seizures for routine clinical, and not primarily research objectives (e.g. presurgical evaluation, other diagnostic purposes). The project population will be composed of adult patients who give informed consent independently as well as of children, and adult patients who lack the capacity to consent to matters concerning their personal health care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 12 years or older, suffering from epilepsy
  • Patient undergoing Video-EEG recording
  • Patient at risk of presenting a GTCS during Video-EEG monitoring according to one of the following criteria (i) known to suffer from GTCS, or (ii) considered for Antiepileptic drugs (AED) tapering during Video-EEG (GTCS often occur during Video-EEG as a result of AED tapering for promoting the occurrence of seizures).
  • Patient willing to participate in the study and signed , by patient or legal representative when required.

Exclusion criteria

Exclusion Criteria:

  • Patients aged less than 12 years old
  • Patient not willing to participate in the study, and where from the patient or the legal representative, when required, cannot be obtained - Patient considered not at risk of presenting a GTCS during Video-EEG because they are not known to suffer GTCS and not candidate to AED tapering during Video-EEG.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. duration of PGES

    The primary endpoint of the study is the duration of PGES, as defined by a postictal EEG flattening \<10microvolt over all scalp-EEG leads (time in seconds). When no PGES is observed, the duration will be coded as 0. This will be used as a dependent variable in the primary analysis.

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. Type of GTCS

    According to our previously published classification.

    Time frame: Through study completion, an average of 4 years

  2. GTCS tonic phase duration on video-EEG recording

    In seconds

    Time frame: Through study completion, an average of 4 years

  3. GTCS clonic phase duration on video-EEG recording

    In seconds

    Time frame: Through study completion, an average of 4 years

  4. Postictal upper limb immobility duration on video-EEG recording

    In seconds

    Time frame: Through study completion, an average of 4 years

  5. Postictal whole-body immobility duration on video-EEG recording

    In seconds

    Time frame: Through study completion, an average of 4 years

  6. Postictal confusion duration on video-EEG recording

    In seconds

    Time frame: Through study completion, an average of 4 years

  7. Postictal bradycardia presence on Electrocardiogram (EKG)

    Yes or No

    Time frame: Through study completion, an average of 4 years

  8. Postictal bradycardia duration on EKG

    In seconds

    Time frame: Through study completion, an average of 4 years

  9. Postictal bradycardia nadir on EKG

    Heart rate per minute

    Time frame: Through study completion, an average of 4 years

  10. Postictal hypoxemia presence on pulse oxymetry

    Yes or No

    Time frame: Through study completion, an average of 4 years

  11. Postictal hypoxemia duration on pulse oxymetry

    In seconds

    Time frame: Through study completion, an average of 4 years

  12. Postictal hypoxemia nadir

    Spo2 value in %

    Time frame: Through study completion, an average of 4 years

  13. Peri-ictal tachycardia or bradycardia presence

    Yes or No

    Time frame: Through study completion, an average of 4 years

  14. Peri-ictal tachycardia or bradycardia duration

    In seconds

    Time frame: Through study completion, an average of 4 years

  15. Peri-ictal tachycardia or bradycardia intensity

    Heart rate per minute

    Time frame: Through study completion, an average of 4 years

  16. Abnormal heart-rate variability during the interictal period

    Inter bits per millisecond

    Time frame: Through study completion, an average of 4 years

07

Study locations

1 site
  • NeuroDigital@NeuroTech
    Lausanne, 1011, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05477121
Responsible party
Philippe Ryvlin (Professor, head of the department of clinical neurosciences, principal investigator, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Jul 28, 2022
Start date
Jun 12, 2019
Primary completion
Dec 31, 2023
Completion
Dec 31, 2024
Last update
Feb 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion